Genzyme to buy Bone Care, widen Hectorol approval

05/5/2005 | MarketWatch

Genzyme said it plans to buy Bone Care International, make it part of Genzyme's U.S. renal operations and take advantage of the firm's $119 million cash on hand. Genzyme said it plans to register Bone Care's Hectorol, for treating secondary hyperparathyroidism associated with kidney dialysis, in other countries after it completes the estimated $600 million acquisition.

View Full Article in:

MarketWatch

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN